Neoadjuvant progesterone therapy for primary breast cancer: rationale for a clinical trial.
The hormonal milieu at the time of surgery may influence mortality and disease-free survival in patients with primary breast cancer. Indeed, there is evidence that circulating unopposed estrogen is detrimental and that the presence of circulating progesterone results in an improved disease-free and overall survival rate. Thus patients who receive neoadjuvant progesterone therapy may have a better outcome. A randomized controlled trial in which women with primary breast cancer receive either progesterone or placebo before surgery is urgently needed to confirm this hypothesis.
Jatoi
I
I
Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D017697:Premenopause; D011374:Progesterone / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D011374:Progesterone